ERBB2 and breast carcinoma: CDK4/6 inhibitors have been approved for treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 (HER2) negative (HER2-) breast cancer in combination with anti-hormonal therapy [13–15].